Statin drugs may lessen the risk for return of prostate cancer in individuals who have undergone radical prostatectomy.
AUGS Clinical Consensus Statement on Postoperative Urinary Retention
Postoperative urinary retention is a common outcome after surgical procedures for pelvic organ prolapse and stress urinary incontinence.
Dr. Schwen on focal therapies for prostate cancer
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
Tumor biology may affect response to kidney cancer treatment, study finds
In total, the investigators assessed data from 886 patients with advanced kidney cancer who were randomly assigned to receive avelumab plus axitinib or subitinib.
Speaking of Urology: Liquid biopsy in prostate cancer
In this episode, David M. Albala, MD, and Sanoj Punnen, MD, discuss precision medicine and the use of biomarker tests in prostate cancer screening and detection.
Treatment begins in study of gedatolisib plus darolutamide in mCRPC
The CELC-G-201 trial is assessing the safety, preliminary efficacy, and pharmacokinetics of gedatolisib plus darolutamide in mCRPC
PSMA-PET leads imaging breakthroughs in prostate cancer paradigm
Daniel Spratt, MD, highlights the evolving paradigm of PET-based imaging agents in prostate cancer, with a focus on the impact of PSMA-PET imaging.
2 Commerce Drive Cranbury, NJ 08512